Literature DB >> 20079948

Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?

Adi F Gazdar1, Boning Gao, John D Minna.   

Abstract

Multiple cell lines (estimated at 300-400) have been established from human small cell (SCLC) and non-small cell lung cancers (NSCLC). These cell lines have been widely dispersed to and used by the scientific community worldwide, with over 8000 citations resulting from their study. However, there remains considerable skepticism on the part of the scientific community as to the validity of research resulting from their use. These questions center around the genomic instability of cultured cells, lack of differentiation of cultured cells and absence of stromal-vascular-inflammatory cell compartments. In this report we discuss the advantages and disadvantages of the use of cell lines, address the issues of instability and lack of differentiation. Perhaps the most important finding is that every important, recurrent genetic and epigenetic change including gene mutations, deletions, amplifications, translocations and methylation-induced gene silencing found in tumors has been identified in cell lines and vice versa. These "driver mutations" represented in cell lines offer opportunities for biological characterization and application to translational research. Another potential shortcoming of cell lines is the difficulty of studying multistage pathogenesis in vitro. To overcome this problem, we have developed cultures from central and peripheral airways that serve as models for the multistage pathogenesis of tumors arising in these two very different compartments. Finally the issue of cell line contamination must be addressed and safeguarded against. A full understanding of the advantages and shortcomings of cell lines is required for the investigator to derive the maximum benefit from their use. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20079948      PMCID: PMC3110769          DOI: 10.1016/j.lungcan.2009.12.005

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  94 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  HeLa cells 50 years on: the good, the bad and the ugly.

Authors:  John R Masters
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

3.  Immortalization and transformation of primary human airway epithelial cells by gene transfer.

Authors:  Ante S Lundberg; Scott H Randell; Sheila A Stewart; Brian Elenbaas; Kimberly A Hartwell; Mary W Brooks; Mark D Fleming; John C Olsen; Scott W Miller; Robert A Weinberg; William C Hahn
Journal:  Oncogene       Date:  2002-07-04       Impact factor: 9.867

4.  Notch signaling induces cell cycle arrest in small cell lung cancer cells.

Authors:  V Sriuranpong; M W Borges; R K Ravi; D R Arnold; B D Nelkin; S B Baylin; D W Ball
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

5.  Genetic and epigenetic changes in human epithelial cells immortalized by telomerase.

Authors:  D G Farwell; K A Shera; J I Koop; G A Bonnet; C P Matthews; G W Reuther; M D Coltrera; J K McDougall; A J Klingelhutz
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

6.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.

Authors:  R Dammann; C Li; J H Yoon; P L Chin; S Bates; G P Pfeifer
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

7.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression.

Authors:  D G Burbee; E Forgacs; S Zöchbauer-Müller; L Shivakumar; K Fong; B Gao; D Randle; M Kondo; A Virmani; S Bader; Y Sekido; F Latif; S Milchgrub; S Toyooka; A F Gazdar; M I Lerman; E Zabarovsky; M White; J D Minna
Journal:  J Natl Cancer Inst       Date:  2001-05-02       Impact factor: 13.506

8.  Personalized medicine and inhibition of EGFR signaling in lung cancer.

Authors:  Adi F Gazdar
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

Review 9.  Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.

Authors:  A F Gazdar
Journal:  Oncogene       Date:  2009-08       Impact factor: 9.867

10.  Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.

Authors:  Junichi Soh; Naoki Okumura; William W Lockwood; Hiromasa Yamamoto; Hisayuki Shigematsu; Wei Zhang; Raj Chari; David S Shames; Ximing Tang; Calum MacAulay; Marileila Varella-Garcia; Tõnu Vooder; Ignacio I Wistuba; Stephen Lam; Rolf Brekken; Shinichi Toyooka; John D Minna; Wan L Lam; Adi F Gazdar
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

View more
  49 in total

1.  Bromodomain and hedgehog pathway targets in small cell lung cancer.

Authors:  Gurmeet Kaur; Russell A Reinhart; Anne Monks; David Evans; Joel Morris; Eric Polley; Beverly A Teicher
Journal:  Cancer Lett       Date:  2015-12-10       Impact factor: 8.679

2.  The clinical relevance of cancer cell lines.

Authors:  Jean-Pierre Gillet; Sudhir Varma; Michael M Gottesman
Journal:  J Natl Cancer Inst       Date:  2013-02-21       Impact factor: 13.506

Review 3.  Lung cancer cell lines as tools for biomedical discovery and research.

Authors:  Adi F Gazdar; Luc Girard; William W Lockwood; Wan L Lam; John D Minna
Journal:  J Natl Cancer Inst       Date:  2010-08-02       Impact factor: 13.506

4.  Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.

Authors:  Eric Polley; Mark Kunkel; David Evans; Thomas Silvers; Rene Delosh; Julie Laudeman; Chad Ogle; Russell Reinhart; Michael Selby; John Connelly; Erik Harris; Nicole Fer; Dmitriy Sonkin; Gurmeet Kaur; Anne Monks; Shakun Malik; Joel Morris; Beverly A Teicher
Journal:  J Natl Cancer Inst       Date:  2016-05-31       Impact factor: 13.506

Review 5.  An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines.

Authors:  Julie Dutil; Zhihua Chen; Alvaro N Monteiro; Jamie K Teer; Steven A Eschrich
Journal:  Cancer Res       Date:  2019-03-20       Impact factor: 12.701

6.  Mdm4 supports DNA replication in a p53-independent fashion.

Authors:  Kai Wohlberedt; Ina Klusmann; Polina K Derevyanko; Kester Henningsen; Josephine Ann Mun Yee Choo; Valentina Manzini; Anna Magerhans; Celeste Giansanti; Christine M Eischen; Aart G Jochemsen; Matthias Dobbelstein
Journal:  Oncogene       Date:  2020-05-19       Impact factor: 9.867

Review 7.  Circulating tumor cells and CDX models as a tool for preclinical drug development.

Authors:  Alice Lallo; Maximilian W Schenk; Kristopher K Frese; Fiona Blackhall; Caroline Dive
Journal:  Transl Lung Cancer Res       Date:  2017-08

8.  MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs.

Authors:  Liqin Du; Jeoffrey J Schageman; Luc Girard; Scott M Hammond; John D Minna; Adi F Gazdar; Alexander Pertsemlidis
Journal:  J Exp Clin Cancer Res       Date:  2010-06-17

9.  Variability in APOE genotype status in human-derived cell lines: a cause for concern in cell culture studies?

Authors:  Sebastian Schaffer; Vanessa Y M Lam; Insa M A Ernst; Patricia Huebbe; Gerald Rimbach; Barry Halliwell
Journal:  Genes Nutr       Date:  2013-12-03       Impact factor: 5.523

Review 10.  Technologies for deriving primary tumor cells for use in personalized cancer therapy.

Authors:  Abhisek Mitra; Lopa Mishra; Shulin Li
Journal:  Trends Biotechnol       Date:  2013-04-16       Impact factor: 19.536

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.